{"ATC Code":"N01AH03","Abbreviation":"","Aliases":["SUFENTANIL","Chronogesic","Sufentanilum","Zalviso","Sufentanilum [INN-Latin]","Sufentanilo","AFE2YW0IIZ","N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide","R-30730","N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide"],"Biological Half-Life":"The elimination half-life is 164 minutes in adults when administered intravenously (IV). The elimination half-life of sufentanil is shorter (e.g. 97 +/- 42 minutes) in infants and children, and longer in neonates (e.g. 434 +/- 160 minutes) compared to that of adolescents and adults.  After a single administration of a 15 microgram sufentanil sublingual tablet, mean terminal phase half-lives in the range of 6-10 hours have been observed. After multiple administrations, a longer average terminal half-life of up to 18 hours was measured, owing to the higher plasma concentrations of sufentanil achieved after repeated dosing and due to the possibility to quantify these concentrations over a longer time period.","CAS":"56030-54-7","ChEBI":"CHEBI:9316","ChEMBL":"CHEMBL658","ChemicalClasses":["piperidine"],"Chirality":"achiral","Color/Form":"Crystals from petroleum ether","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates","Drug Indication":"The indications for this drug are as follows:  1. As an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.  2. As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.  3. For epidural administration as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery   4. The sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments.","Drug Warnings":"/BOXED WARNING/ WARNING: ADDICTION, ABUSE, AND MISUSE. Sufentanil citrate injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly for these behaviors and conditions.","DrugClasses":["opioid"],"European Community (EC) Number":"641-081-8","FDA Pharmacological Classification":"AFE2YW0IIZ","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates","IUPACName":"N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide","Impurities":["(4-(phenylpropanoylamino)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)methyl propanoate","(4-(phenylamino)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)methanol","butanamide, n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-n-phenyl-","n-(4-(methoxymethyl)-1-(2-(3-thienyl)ethyl)-4-piperidinyl)-n-phenylpropanamide","trans-4-(methoxymethyl)-4-(phenylpropanoylamino)-1-(2-(thiophen-2-yl)ethyl)piperidine 1-oxide","4-(methoxymethyl)-n-phenyl-1-(2-(2-thienyl)ethyl)-4-piperidinamine","cis-4-(methoxymethyl)-4-(phenylpropanoylamino)-1-(2-(thiophen-2-yl)ethyl)piperidine 1-oxide","noralfentanil"],"InChI":"InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3","InChIKey":"GGCSSNBKKAUURC-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)","Melting Point":"96.6 °C","MolecularFormula":"C\u003csub\u003e22\u003c/sub\u003eH\u003csub\u003e30\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003eS","MolecularWeight":"386.6 g/mol","Pharmacodynamics":"**Effect on the Central Nervous System (CNS)**   In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary therapeutic actions are analgesia and sedation. Sufentanil may increase pain tolerance and decrease the perception of pain. This drug depresses the respiratory centers, depresses the cough reflex, and constricts the pupils,. When used in balanced general anesthesia, sufentanil has been reported to be as much as 10 times as potent as fentanyl. When administered intravenously as a primary anesthetic agent with 100% oxygen, sufentanil is approximately 5 to 7 times as potent as fentanyl. High doses of intravenous sufentanil have been shown to cause muscle rigidity, likely as a result of an effect on the substantia nigra and the striate nucleus in the brain. Sleep-inducing (hypnotic) activity can be demonstrated by EEG alterations.  **Effects on the Respiratory System**  Sufentanil may cause respiratory depression.  **Effects on the Cardiovascular System**  Sufentanil causes peripheral vasodilation which may result in orthostatic hypotension or syncope. Bradycardia may also occur. Clinical signs or symptoms of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.  **Effects on the Gastrointestinal Tract**  Sufentanil causes a reduction in motility associated with an increase in smooth muscle tone in both the antrum of the stomach and duodenum. Digestion of food in the small intestine may be delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased and lead to spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of the sphincter of Oddi, as well as temporary elevations in serum amylase.","Physical Description":"Solid","PubChemId":41693,"Record Description":["Sufentanil is an anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant and an intravenous anaesthetic. It is a member of piperidines, a member of thiophenes, an anilide and an ether.","Sufentanil is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence. It is a Opiates substance.","Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.  It is administered by the intravenous, epidural and sublingual routes.   Also known as Dsuvia, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately.  The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration,.","Sufentanil is an Opioid Agonist. The mechanism of action of sufentanil is as a Full Opioid Agonist.","SUFENTANIL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 7 investigational indications. This drug has a black box warning from the FDA.","Sufentanil is only found in individuals that have used or taken this drug. It is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.","An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.","See also: Sufentanil Citrate (has salt form).","Sufentanil is an anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant and an intravenous anaesthetic. It is a member of piperidines, a member of thiophenes, an anilide and an ether.","LiverTox|Analgesic|Severe pain|Opiate","WIKIPEDIA|FENTANYL ANALOGUES","Sufentanil first was synthesized at Janssen Pharmaceutica in 1974. Sufentanil is marketed for use by specialist centers under different trade names, such as Sufenta and Sufentil. Sufentanil with and without lidocaine or mepivacaine is available as a transdermal patch similar to Duragesic in Europe under trade names such as Chronogesic."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Sufentanil"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q417915"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00708"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/41693"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.38043.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL658"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9316"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=56030-54-7"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014846"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C08022"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/AFE2YW0IIZ"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023604"}],"SMILES":"CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC","Salts":["hydrochloride","citrate"],"Solubility":"Soluble","Stability/Shelf Life":"Stable under recommended storage conditions. /Sufentanil citrate/","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.526mm" version="1.2" viewBox="0 0 146.02 91.526" width="146.02mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="147.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="145.011" x2="130.691" y1="44.813" y2="50.027"/>
                  
            <line class="bond" id="mol1bnd2" x1="130.691" x2="119.015" y1="50.027" y2="40.232"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="117.692" x2="119.772" y1="40.714" y2="28.912"/>
                        
                <line x1="120.094" x2="122.174" y1="41.137" y2="29.335"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="119.772" x2="118.732" y1="28.912" y2="34.813"/>
                <line class="hi" stroke="#FF0D0D" x1="122.174" x2="121.134" y1="29.335" y2="35.236000000000004"/>
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="119.015" x2="107.951" y1="40.232" y2="44.261"/>
                  
            <line class="bond" id="mol1bnd5" x1="104.02" x2="102.05" y1="49.275" y2="60.455"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="102.05" x2="87.72" y1="60.455" y2="65.667"/>
                        
                <line x1="101.562" x2="89.877" y1="63.228" y2="67.478"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="87.72" x2="85.075" y1="65.667" y2="80.676"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="85.075" x2="96.761" y1="80.676" y2="90.473"/>
                        
                <line x1="87.721" x2="97.249" y1="79.712" y2="87.7"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="96.761" x2="111.091" y1="90.473" y2="85.26"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="111.091" x2="113.735" y1="85.26" y2="70.252"/>
                        
                <line x1="108.934" x2="111.09" y1="83.45" y2="71.215"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="102.05" x2="113.735" y1="60.455" y2="70.252"/>
                  
            <line class="bond" id="mol1bnd12" x1="101.682" x2="93.019" y1="42.918" y2="35.652"/>
                  
            <line class="bond" id="mol1bnd13" x1="93.019" x2="85.399" y1="35.652" y2="22.444"/>
                  
            <line class="bond" id="mol1bnd14" x1="85.399" x2="70.159" y1="22.444" y2="22.444"/>
                  
            <line class="bond" id="mol1bnd15" x1="70.159" x2="64.652" y1="22.444" y2="31.989"/>
                  
            <line class="bond" id="mol1bnd16" x1="64.652" x2="70.159" y1="39.314" y2="48.86"/>
                  
            <line class="bond" id="mol1bnd17" x1="70.159" x2="85.399" y1="48.86" y2="48.86"/>
                  
            <line class="bond" id="mol1bnd18" x1="93.019" x2="85.399" y1="35.652" y2="48.86"/>
                  
            <line class="bond" id="mol1bnd19" x1="59.198" x2="47.299" y1="35.652" y2="35.652"/>
                  
            <line class="bond" id="mol1bnd20" x1="47.299" x2="39.679" y1="35.652" y2="22.453"/>
                  
            <line class="bond" id="mol1bnd21" x1="39.679" x2="24.439" y1="22.453" y2="22.453"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="24.439" x2="15.49" y1="22.453" y2="10.091"/>
                        
                <line x1="21.429" x2="14.557" y1="22.453" y2="12.96"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="15.49" x2="1.001" y1="10.091" y2="14.818"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="1.001" x2="1.065" y1="14.818" y2="30.08"/>
                        
                <line x1="3.447" x2="3.496" y1="16.585" y2="28.305"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="1.065" x2="12.687" y1="30.08" y2="33.847"/>
                  
            <line class="bond" id="mol1bnd26" x1="24.439" x2="17.788" y1="22.453" y2="31.641"/>
                  
            <line class="bond" id="mol1bnd27" x1="93.019" x2="104.695" y1="35.652" y2="25.857"/>
                  
            <line class="bond" id="mol1bnd28" x1="104.695" x2="102.737" y1="25.857" y2="14.748"/>
                  
            <line class="bond" id="mol1bnd29" x1="105.011" x2="113.726" y1="8.364" y2="1.053"/>
                  
            <path class="atom" d="M123.919 25.221q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM120.056 25.221q-.0 .922 .387 1.458q.393 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M106.636 47.896h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M64.48 38.101h-.72l-2.62 -4.066h-.029q.012 .238 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm15" stroke="none"/>
                  
            <path class="atom" d="M17.07 35.903q.0 .649 -.476 1.018q-.47 .364 -1.268 .364q-.417 -.0 -.768 -.066q-.345 -.059 -.577 -.173v-.589q.244 .113 .607 .203q.369 .089 .762 .089q.547 -.0 .827 -.214q.28 -.215 .28 -.578q.0 -.238 -.107 -.399q-.101 -.166 -.351 -.309q-.25 -.143 -.697 -.298q-.625 -.226 -.946 -.554q-.316 -.333 -.316 -.899q.0 -.392 .197 -.666q.202 -.28 .553 -.429q.357 -.155 .816 -.155q.405 .0 .738 .078q.339 .071 .613 .196l-.196 .53q-.25 -.113 -.548 -.185q-.298 -.077 -.625 -.077q-.458 .0 -.691 .196q-.232 .197 -.232 .518q.0 .244 .101 .411q.108 .167 .34 .298q.232 .125 .631 .28q.428 .154 .726 .339q.298 .179 .452 .435q.155 .25 .155 .636z" fill="#C6C62C" id="mol1atm24" stroke="none"/>
                  
            <path class="atom" d="M104.309 10.845q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM100.446 10.845q-.0 .923 .387 1.459q.393 .529 1.22 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm26" stroke="none"/>
                
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="107.951" x2="113.483" y1="44.261" y2="42.2465"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="104.02" x2="103.035" y1="49.275" y2="54.864999999999995"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="101.682" x2="97.35050000000001" y1="42.918" y2="39.285"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="64.652" x2="67.4055" y1="31.989" y2="27.2165"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="64.652" x2="67.4055" y1="39.314" y2="44.087"/>
            <line class="hi" id="mol1bnd19" stroke="#3050F8" x1="59.198" x2="53.2485" y1="35.652" y2="35.652"/>
            <line class="hi" id="mol1bnd25" stroke="#C6C62C" x1="12.687" x2="6.8759999999999994" y1="33.847" y2="31.9635"/>
            <line class="hi" id="mol1bnd26" stroke="#C6C62C" x1="17.788" x2="21.113500000000002" y1="31.641" y2="27.046999999999997"/>
            <line class="hi" id="mol1bnd28" stroke="#FF0D0D" x1="102.737" x2="103.716" y1="14.748" y2="20.3025"/>
            <line class="hi" id="mol1bnd29" stroke="#FF0D0D" x1="105.011" x2="109.3685" y1="8.364" y2="4.708500000000001"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Analgesics, Opioid; Adjuvants, Anesthesia; Narcotics; Anesthetics, Intravenous","Title":"Sufentanyl","UNII":"AFE2YW0IIZ","Wikidata":"Q417915","XLogP":4}